Datapoint: FDA Approves First Once-Daily Uterine Fibroids Drug

The FDA on May 25 approved Myovant Sciences’ and Pfizer’s Myfembree for the treatment of heavy menstrual bleeding caused by uterine fibroids in premenopausal women. In a Phase 3 trial, women taking Myfembree saw reductions in menstrual blood loss of more than 80%. Myovant and Pfizer will have to compete against AbbVie and Neurocrine Biosciences’ Oriahnn, which the FDA approved in May 2020 as the first-ever oral therapy for uterine fibroids. While Oriahnn must be taken twice per day, Myfembree is a once-daily treatment. Under the pharmacy benefit, Oriahnn holds covered or better status for 70% of all insured lives. It holds preferred formulary placement for 44.6% of covered lives.

SOURCE: MMIT Analytics, as of 6/2/2021

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 2

Datapoint: Amgen Asks Supreme Court to Hear Repatha Case

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 1

Datapoint: United to Join Massachusetts Duals Demo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 30

Datapoint: Oscar, Emory to Offer New Health Plan in Georgia

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today